Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis

The American Journal of Medicine
Samy SuissaAbbas Kezouh

Abstract

Spontaneous cases of hepatic adverse events have been reported in patients with rheumatoid arthritis who were being treated with leflunomide, one of the newer disease-modifying antirheumatic drugs (DMARDs). We assessed the risk of hepatic events associated with the use of leflunomide and other DMARDs. Two cohorts comprising 41,885 patients with rheumatoid arthritis who had been dispensed a DMARD between September 1, 1998, and December 31, 2001, were formed using claims databases. Follow-up was from the first dispensing date to the occurrence of a serious or nonserious hepatic event. A nested case-control approach was used to estimate adjusted rate ratios of hepatic events associated with DMARDs dispensed during the prior year, as compared with methotrexate monotherapy. There were 25 cases of serious hepatic events (rate, 4.9 per 10,000 per year) and 411 nonserious hepatic events (rate, 80.0 per 10,000 per year). There was no increase in the rate of serious hepatic events with either leflunomide (rate ratio [RR] = 0.9; 95% confidence interval [CI]: 0.2 to 4.9) or traditional DMARDs (RR = 2.3; 95% CI: 0.8 to 6.5). However, the rate was increased with biologic DMARDs (RR = 5.5; 95% CI: 1.2 to 24.6). The rate of nonserious hepatic ...Continue Reading

Citations

Nov 27, 2007·Nature Clinical Practice. Rheumatology·Samy Suissa, Edeltraut Garbe
Jan 26, 2011·Nature Reviews. Rheumatology·Guruprasad P Aithal
May 15, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Aaron J KatzPaul E Stang
Jun 12, 2013·Research in Social & Administrative Pharmacy : RSAP·Richard A HansenDavid Mark Carpenter
Nov 30, 2010·Clinics in Liver Disease·Christine SchlenkerKris V Kowdley
May 20, 2008·Gastroentérologie Clinique Et Biologique·D Larrey
May 23, 2007·Pulmonary Pharmacology & Therapeutics·Samy SuissaMarie Hudson
Dec 22, 2012·Pharmacoepidemiology and Drug Safety·Janet ShinT Craig Cheetham
Jun 7, 2005·Expert Opinion on Pharmacotherapy·J Peter Kaltwasser, Frank Behrens
Oct 11, 2014·Seminars in Arthritis and Rheumatism·Jeffrey R CurtisUNKNOWN Actemra Pharmacoepidemiology Board
Apr 29, 2006·Arthritis and Rheumatism·Samy SuissaPierre Ernst
Jul 29, 2006·Arthritis and Rheumatism·Samy SuissaMarie Hudson
Mar 11, 2005·Rheumatology·V GoëbX Le Loët
Jun 11, 2009·Current Opinion in Organ Transplantation·Nicolae Leca
Nov 18, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Nicola AlcornRajan Madhok
Jan 1, 2006·Expert Review of Clinical Immunology·Gary Kunkel, Grant W Cannon
Nov 7, 2012·Therapeutic Drug Monitoring·Maria Grazia AnelliGiovanni Lapadula

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
C Sevilla-MantillaM Díaz-Rubio
Drug Safety : an International Journal of Medical Toxicology and Drug Experience
Eric N van RoonJacobus R B J Brouwers
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Paul BrassardSamy Suissa
© 2022 Meta ULC. All rights reserved